52662 Federal Register / Vol. 73, No. 176 / Wednesday, September 10, 2008 / Notices 

Synopsis: The amendment would add 

Evergreen Line Joint Service Agreement 

as a non-shareholder party to the 

agreement. 

Agreement No.: 012048. 

Title: The Container Trades Statistics 

Agreement. 

Parties: A.P. Moeller-Maersk A/S; 

China Shipping Container Lines Co., 

Ltd.; COSCO Container Lines Company 

Ltd.; CMA CGM S.A.; Compania 

Sudamericana de Vapores S.A.; 

Evergreen Line Joint Service Agreement; 

Hamburg Sud KG; Hanjin Shipping Co., 

Ltd.; Hapag-Lloyd AG; Hyundai 

Merchant Marine Co., Ltd.; Independent 

Container Line Ltd.; Kawasaki Kisen 

Kaisha, Ltd.; Mediterranean Shipping 

Co. S.A.; Mitsui O.S.K. Lines, Ltd.; 

Nippon Yusen Kaisha; Orient Overseas 

Container Line Ltd.; Pacific 

International Lines (PTE) Ltd.; United 

Arab Shipping Co. (SAG); Yangming 

Marine Transport Corp.; and Zim 

Integrated Shipping Services, Ltd. 

Filing Party: Wayne R. Rohde, Esq., 

Sher & Blackwell LLP, 1850 M Street, 

NW., Suite 900, Washington, DC 20036. 

Synopsis: The agreement authorizes 

the parties to gather, compile, aggregate, 

exchange, and disseminate demand and 

supply forecasts, a volume database, 

and a price index relating to the trade 

between the United States and the 

European Union. It also authorizes the 

parties to meet and discuss such data. 

By Order of the Federal Maritime 

Commission. 

Dated: September 5, 2008. 

Karen V. Gregory, 

Assistant Secretary. 

[FR Doc. E8–21034 Filed 9–9–08; 8:45 am] 

BILLING CODE 6730–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR Part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications also will be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than October 3, 

2008. 

A. Federal Reserve Bank of St. Louis 

(Glenda Wilson, Community Affairs 

Officer) 411 Locust Street, St. Louis, 

Missouri 63166-2034: 

1. Heritage Bancorp, Inc., Mason, 

Tennessee; to directly acquire 2.12 

percent, for total direct and indirect 

ownership of 51.77 percent, of Mason 

Bancorp, Inc., Mason, Tennessee, and 

thereby indirectly acquire The Bank of 

Mason, Mason Tennessee. 

Board of Governors of the Federal Reserve 

System, September 5, 2008. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E8–20958 Filed 9–9–08; 8:45 am] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–08–0494] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Maryam I. Daneshvar, 

CDC Acting Reports Clearance Officer, 

1600 Clifton Road, MS–D74, Atlanta, 

GA 30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Exposure to Aerosolized Brevetoxins 

during Red Tide Events (OMB No. 

0920–0494)—Revision—National Center 

for Environmental Health (NCEH), 

Centers for Disease Control and 

Prevention (CDC.) 

Background and Brief Description 

Karenia brevis (formerly 

Gymnodinium breve) is the marine 

dinoflagellate responsible for extensive 

blooms (called Florida red tides) that 

forms in the Gulf of Mexico. K. brevis 

produces potent toxins, called 

brevetoxins, which have been 

responsible for killing millions of fish 

and other marine organisms. The 

biochemical activity of brevetoxins is 

not completely understood and there is 

still little information regarding human 

health effects from environmental 

exposures, such as inhaling brevetoxin 

that has been aerosolized and swept 

onto the coast by offshore winds. The 

National Center for Environmental 

Health (NCEH), Centers for Disease 

Control and Prevention (CDC) has 

recruited people who work along the 

coast of Florida and who are 

periodically occupationally exposed to 

aerosolized red tide toxins. 

NCEH administered a baseline 

respiratory health survey and conducted 

pre- and post-shift pulmonary function 

tests (PFTs) during a time when there is 

no red tide reported near the area. When 

a red tide developed, NCEH 

administered a symptom survey and 

conducted PFTs. NCEH compared 

symptoms reported before the shift with 

symptoms reported after the shift. NCEH 

also examined changes in PFT test 

results (post-shift values compared to 

pre-shift values). NCEH did these 

comparisons during a time when there 

was no red tide and during a time when 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 73, No. 176 / Wednesday, September 10, 2008 / Notices 52663 

there was a red tide and then examined 

the data to see if red tide exposure had 

an effect on symptom reports or PFT 

results. 

NCEH requests a revision of data 

collection procedures for the currently 

approved project and an additional 

three year extension. Unfortunately, the 

exposures experienced by the study 

cohort have been minimal, and NCEH 

plans to conduct another study (using 

the same symptom surveys and PFTs) 

during a more severe red tide event. 

First, NCEH wants to quantify the levels 

of cytokines in nasal exudates to assess 

whether they can be used to verify 

exposure and to demonstrate a 

biological effect (i.e., allergic response) 

following inhalation of aerosolized 

brevetoxins. NCEH will collect nasal 

exudates at the same time the PFTs are 

done. 

NCEH plans to include the study 

subjects who have been involved in the 

earlier studies and any new individuals 

(n=25) who have been hired to work at 

the relevant beaches. 

There is no cost to respondents other 

than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Instrument type Number of respondents 

Number of responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Pulmonary History Survey ............................................................................... 10 1 20/60 3 

Symptom survey .............................................................................................. 25 6 5/60 13 

Total .......................................................................................................... ........................ ........................ ........................ 16 

Catina Conner, 

Assistant Reports Clearance Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. E8–20913 Filed 9–9–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Ethics Subcommittee, Advisory 

Committee to the Director, Centers for 

Disease Control and Prevention (CDC); 

Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention announce the 

following Subcommittee meeting. 

Name: Ethics Subcommittee, Advisory 

Committee to the Director. 

Time and Date: 12 p.m.–1:30 p.m., EDT, 

Thursday, September 25, 2008. 

Place: This meeting will be held by 

conference call. The call in number is (866) 

919–3560 and entering code 4168828. 

Status: Open to the public. The public is 

welcome to comment during the public 

comment period which is tentatively 

scheduled from 1 p.m.–1:15 p.m. 

Purpose: The Ethics Subcommittee will 

provide counsel to the ACD, CDC regarding 

a broad range of public health ethics 

questions and issues arising from programs, 

scientists and practitioners. 

Matters To Be Discussed: Agenda items 

will include review of ethics guidance for 

public health emergency preparedness and 

response. 

For Further Information Contact: For more 

information about this meeting contact Drue 

Barrett, PhD., Designated Federal Official, 

Ethics Subcommittee, CDC, 1600 Clifton 

Road, NE., M/S D–50, Atlanta, Georgia 

30333, Telephone (404)639–4690, e-mail: 

dbarrett@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: September 4, 2008. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E8–20967 Filed 9–9–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0239] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Regulations for In 

Vivo Radiopharmaceuticals Used for 

Diagnosis and Monitoring 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by October 10, 

2008. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–6974, or e-mailed to 

baguilar@omb.eop.gov. All comments 

should be identified with the OMB 

control number 0910–0409. Also 

include the FDA docket number found 

in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Elizabeth Berbakos, Office of 

Information Management (HFA–710), 

Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

301–796–3792. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Regulations for In Vivo 

Radiopharmaceuticals Used for 

Diagnosis and Monitoring (OMB 

Control Number 0910–0409)—Extension 

FDA is requesting OMB approval of 

the information collection requirements 

contained in 21 CFR 315.4, 315.5, and 

315.6. These regulations require 

manufacturers of diagnostic 

radiopharmaceuticals to submit 

information that demonstrates the safety 

and effectiveness of a new diagnostic 

radiopharmaceutical or of a new 

indication for use of an approved 

diagnostic radiopharmaceutical. 

In response to the requirements of 

section 122 of the Food and Drug 

Administration Modernization Act of 

1997 (Public Law 105–115), FDA 

published a final rule in the Federal 


pwalker on PROD1PC71 with NOTICES